Explore ViiV Healthcare
Report adverse event
If you are a patient and have experienced an unexpected event when taking one of our medications please speak to your healthcare professional as soon as possible. To lodge a report contact:
Phone: 1800 499 226
Cabenuva (cabotegravir/rilprivirine) is listed on the Australian Register of Therapeutic Goods (ARTG).
CABENUVA is used to treat Human Immunodeficiency Virus (HIV) infection in adults aged 18 years and over. CABENUVA is a complete, long-acting regimen administered every 2-months and contains two medicines, cabotegravir prolonged-release suspension for injection and rilpivirine prolonged release suspension for injection, packaged together.
CABENUVA does not cure HIV infection; it keeps the amount of virus in your body at a low level.
Date of Preparation: February 2021. PM-AU-CBR-WCNT-210001